Share Price and Basic Stock Data
Last Updated: October 8, 2025, 11:41 pm
| PEG Ratio | 13.18 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Bayer CropScience Ltd, a prominent player in the agrochemicals sector, reported a price of ₹4,995 and a market capitalization of ₹22,413 Cr. The company’s revenue trends have shown notable fluctuations over the past quarters. For instance, sales recorded in June 2022 stood at ₹1,667 Cr, subsequently declining to ₹982 Cr by March 2023. However, a resurgence was observed in June 2023 with sales rising to ₹1,740 Cr, followed by a steady upward trend to ₹1,915 Cr in June 2025. The overall sales for FY 2025 reached ₹5,473 Cr, demonstrating resilience despite challenges. This trend indicates a potential recovery in market demand and operational efficiency, positioning Bayer CropScience favorably within the agrochemical industry, which has been experiencing increased competition and regulatory scrutiny. The company’s ability to adapt to market dynamics will be crucial for sustaining these revenue levels in the future.
Profitability and Efficiency Metrics
The profitability metrics for Bayer CropScience highlight both strengths and weaknesses. The operating profit margin (OPM) fluctuated significantly, with peaks of 24% in June 2023 and December 2022, but declining to 12% by March 2024. The net profit for FY 2025 was reported at ₹568 Cr, with an earnings per share (EPS) of ₹126.38, reflecting a decline from the ₹168.71 EPS in FY 2023. The return on equity (ROE) stood at 20%, while the return on capital employed (ROCE) was reported at 24.8%. The interest coverage ratio (ICR) remained robust at 47.61x, indicating a strong ability to cover interest expenses. However, the cash conversion cycle (CCC) of 234 days suggests potential inefficiencies in managing working capital, which could impact liquidity if not addressed. These metrics underscore the need for Bayer CropScience to enhance operational efficiency to maintain profitability amidst fluctuating sales figures.
Balance Sheet Strength and Financial Ratios
Bayer CropScience’s balance sheet exhibits a solid structure, with total reserves rising to ₹2,806 Cr against borrowings of ₹105 Cr, reflecting a strong equity position. The debt-to-equity ratio is notably low, indicating prudent financial management and minimal reliance on external debt. The company’s current ratio of 2.01 suggests a comfortable liquidity position, while the quick ratio of 0.94 indicates potential liquidity concerns in meeting short-term obligations. The price-to-book value (P/BV) ratio stood at 7.76x, indicating that the stock may be considered overvalued compared to its book value. Additionally, the operating profit of ₹924 Cr for FY 2023 and the interest coverage ratio of 47.61x reinforce the company’s ability to service its debt effectively. These financial ratios highlight Bayer CropScience’s overall financial health, although attention to liquidity management will be essential moving forward.
Shareholding Pattern and Investor Confidence
Bayer CropScience’s shareholding structure reveals a significant promoter stake of 71.44%, indicating strong control and confidence from the founding shareholders. Foreign institutional investors (FIIs) held 3.64%, while domestic institutional investors (DIIs) accounted for 11.38%, reflecting moderate institutional interest. The public shareholding stood at 13.55%, with the total number of shareholders reported at 55,753. The steady percentages of promoter and institutional holdings suggest a stable investor base, although the relatively low FII participation may signal caution among foreign investors regarding the company’s market performance. The trends in shareholding over recent quarters have shown slight fluctuations, particularly in DII holdings, which have decreased from 12.76% in September 2022 to 11.38% by March 2025. This pattern may reflect broader market sentiments and investor confidence in the company’s growth prospects.
Outlook, Risks, and Final Insight
If margins sustain and operational efficiencies improve, Bayer CropScience could leverage its strong market position to capitalize on growth opportunities in the agrochemical sector. However, risks such as fluctuating raw material costs, regulatory pressures, and competitive dynamics may pose challenges. The declining trends in sales and profitability metrics must be closely monitored to ensure sustainable growth. Additionally, the company’s ability to manage its cash conversion cycle effectively will be critical in maintaining liquidity and operational flexibility. Overall, Bayer CropScience’s strategic focus on innovation and market responsiveness, coupled with its robust financial health, positions it well for future challenges and opportunities in a rapidly evolving industry landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bayer CropScience Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 7,403 Cr. | 1,716 | 2,362/1,502 | 17.2 | 441 | 0.35 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 1,034 Cr. | 306 | 391/165 | 19.8 | 117 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 55.7 Cr. | 107 | 148/55.2 | 10.2 | 34.1 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 3,223 Cr. | 248 | 392/234 | 113 | 53.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 829 Cr. | 351 | 670/244 | 12.1 | 320 | 0.86 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,449.00 Cr | 1,521.14 | 35.07 | 435.59 | 0.41% | 15.21% | 19.87% | 7.25 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,667 | 1,452 | 1,038 | 982 | 1,740 | 1,617 | 955 | 792 | 1,631 | 1,738 | 1,057 | 1,046 | 1,915 |
| Expenses | 1,272 | 1,214 | 952 | 777 | 1,315 | 1,312 | 827 | 695 | 1,317 | 1,554 | 1,037 | 876 | 1,566 |
| Operating Profit | 395 | 238 | 85 | 206 | 425 | 305 | 128 | 97 | 314 | 184 | 20 | 171 | 348 |
| OPM % | 24% | 16% | 8% | 21% | 24% | 19% | 13% | 12% | 19% | 11% | 2% | 16% | 18% |
| Other Income | 14 | 14 | 116 | 24 | 21 | 16 | 15 | 29 | 27 | 24 | 32 | 37 | 19 |
| Interest | 4 | 8 | 3 | 7 | 8 | 4 | 3 | 5 | 4 | 3 | 4 | 6 | 5 |
| Depreciation | 23 | 15 | 14 | 27 | 31 | 12 | 15 | 16 | 22 | 14 | 15 | 34 | 27 |
| Profit before tax | 382 | 229 | 184 | 195 | 406 | 306 | 124 | 105 | 316 | 190 | 34 | 168 | 335 |
| Tax % | 21% | 29% | 27% | 19% | 19% | 27% | 25% | 9% | 20% | 28% | -2% | 15% | 17% |
| Net Profit | 303 | 163 | 134 | 158 | 328 | 223 | 93 | 96 | 254 | 136 | 34 | 143 | 279 |
| EPS in Rs | 67.33 | 36.18 | 29.93 | 35.27 | 73.09 | 49.60 | 20.72 | 21.36 | 56.56 | 30.33 | 7.61 | 31.89 | 62.01 |
Last Updated: August 19, 2025, 10:35 pm
Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,915.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,046.00 Cr. (Mar 2025) to 1,915.00 Cr., marking an increase of 869.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,566.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 876.00 Cr. (Mar 2025) to 1,566.00 Cr., marking an increase of 690.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 348.00 Cr.. The value appears strong and on an upward trend. It has increased from 171.00 Cr. (Mar 2025) to 348.00 Cr., marking an increase of 177.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Mar 2025) to 18.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 18.00 Cr..
- For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 27.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 34.00 Cr. (Mar 2025) to 27.00 Cr., marking a decrease of 7.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2025) to 335.00 Cr., marking an increase of 167.00 Cr..
- For Tax %, as of Jun 2025, the value is 17.00%. The value appears to be increasing, which may not be favorable. It has increased from 15.00% (Mar 2025) to 17.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 279.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 279.00 Cr., marking an increase of 136.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 62.01. The value appears strong and on an upward trend. It has increased from 31.89 (Mar 2025) to 62.01, marking an increase of 30.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 2:39 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,188 | 3,660 | 2,769 | 2,803 | 2,710 | 3,167 | 3,609 | 4,261 | 4,734 | 5,140 | 5,103 | 5,473 |
| Expenses | 2,768 | 3,144 | 2,334 | 2,389 | 2,300 | 2,684 | 2,883 | 3,450 | 3,923 | 4,216 | 4,147 | 4,784 |
| Operating Profit | 419 | 516 | 435 | 414 | 410 | 483 | 726 | 812 | 812 | 924 | 956 | 690 |
| OPM % | 13% | 14% | 16% | 15% | 15% | 15% | 20% | 19% | 17% | 18% | 19% | 13% |
| Other Income | 91 | 88 | 82 | 70 | 39 | 51 | -64 | 69 | 112 | 168 | 79 | 120 |
| Interest | 5 | 5 | 10 | 7 | 11 | 10 | 14 | 13 | 13 | 22 | 20 | 17 |
| Depreciation | 65 | 25 | 25 | 29 | 33 | 44 | 65 | 74 | 64 | 80 | 74 | 85 |
| Profit before tax | 441 | 574 | 482 | 448 | 404 | 480 | 583 | 794 | 847 | 990 | 941 | 707 |
| Tax % | 34% | 33% | 35% | 35% | 26% | 30% | 19% | 38% | 24% | 23% | 21% | 20% |
| Net Profit | 290 | 383 | 315 | 291 | 300 | 337 | 474 | 493 | 645 | 758 | 740 | 568 |
| EPS in Rs | 79.06 | 104.59 | 89.13 | 82.31 | 87.41 | 98.18 | 105.58 | 109.72 | 143.58 | 168.71 | 164.77 | 126.38 |
| Dividend Payout % | 7% | 20% | 19% | 21% | 21% | 18% | 24% | 105% | 104% | 77% | 85% | 99% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.07% | -17.75% | -7.62% | 3.09% | 12.33% | 40.65% | 4.01% | 30.83% | 17.52% | -2.37% | -23.24% |
| Change in YoY Net Profit Growth (%) | 0.00% | -49.82% | 10.14% | 10.71% | 9.24% | 28.32% | -36.64% | 26.82% | -13.31% | -19.89% | -20.87% |
Bayer CropScience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 0% |
| 3 Years: | -2% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -3% |
| 3 Years: | -1% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 20% |
Last Updated: September 5, 2025, 2:36 pm
Balance Sheet
Last Updated: August 11, 2025, 3:27 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 37 | 37 | 35 | 35 | 34 | 34 | 45 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 1,706 | 1,996 | 1,804 | 2,021 | 1,744 | 2,205 | 2,528 | 2,505 | 2,479 | 2,667 | 2,804 | 2,806 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 26 | 86 | 74 | 47 | 105 |
| Other Liabilities | 645 | 740 | 597 | 769 | 756 | 1,310 | 1,262 | 1,663 | 1,742 | 1,893 | 1,701 | 2,290 |
| Total Liabilities | 2,387 | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 |
| Fixed Assets | 228 | 322 | 290 | 342 | 334 | 440 | 468 | 425 | 468 | 462 | 414 | 470 |
| CWIP | 217 | 1 | 17 | 24 | 36 | 47 | 56 | 76 | 98 | 109 | 119 | 119 |
| Investments | 4 | 29 | 68 | 50 | 0 | 0 | 41 | 52 | 38 | 41 | 54 | 35 |
| Other Assets | 1,939 | 2,422 | 2,062 | 2,410 | 2,164 | 3,062 | 3,270 | 3,686 | 3,749 | 4,066 | 4,010 | 4,622 |
| Total Assets | 2,387 | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 |
Below is a detailed analysis of the balance sheet data for Bayer CropScience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 45.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,806.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,804.00 Cr. (Mar 2024) to 2,806.00 Cr., marking an increase of 2.00 Cr..
- For Borrowings, as of Mar 2025, the value is 105.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 47.00 Cr. (Mar 2024) to 105.00 Cr., marking an increase of 58.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 2,290.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,701.00 Cr. (Mar 2024) to 2,290.00 Cr., marking an increase of 589.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 5,246.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,597.00 Cr. (Mar 2024) to 5,246.00 Cr., marking an increase of 649.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 470.00 Cr.. The value appears strong and on an upward trend. It has increased from 414.00 Cr. (Mar 2024) to 470.00 Cr., marking an increase of 56.00 Cr..
- For CWIP, as of Mar 2025, the value is 119.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 119.00 Cr..
- For Investments, as of Mar 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 54.00 Cr. (Mar 2024) to 35.00 Cr., marking a decrease of 19.00 Cr..
- For Other Assets, as of Mar 2025, the value is 4,622.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,010.00 Cr. (Mar 2024) to 4,622.00 Cr., marking an increase of 612.00 Cr..
- For Total Assets, as of Mar 2025, the value is 5,246.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,597.00 Cr. (Mar 2024) to 5,246.00 Cr., marking an increase of 649.00 Cr..
Notably, the Reserves (2,806.00 Cr.) exceed the Borrowings (105.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 419.00 | 516.00 | 435.00 | 414.00 | 410.00 | 483.00 | 724.00 | 786.00 | 726.00 | 850.00 | 909.00 | 585.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 57 | 53 | 72 | 89 | 81 | 73 | 65 | 77 | 69 | 69 | 63 |
| Inventory Days | 98 | 85 | 169 | 178 | 175 | 294 | 206 | 226 | 235 | 268 | 222 | 319 |
| Days Payable | 51 | 40 | 52 | 67 | 67 | 164 | 101 | 142 | 127 | 129 | 87 | 148 |
| Cash Conversion Cycle | 94 | 102 | 171 | 184 | 197 | 211 | 177 | 149 | 185 | 208 | 204 | 234 |
| Working Capital Days | 88 | 53 | 92 | 104 | 134 | 116 | 77 | 61 | 84 | 86 | 78 | 88 |
| ROCE % | 24% | 31% | 25% | 23% | 22% | 25% | 30% | 31% | 31% | 34% | 34% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Large & Midcap Fund | 792,954 | 1.33 | 449.55 | 792,954 | 2025-04-22 17:25:13 | 0% |
| Nippon India Small Cap Fund | 531,460 | 0.65 | 301.3 | 531,460 | 2025-04-22 17:25:13 | 0% |
| Mirae Asset Midcap Fund | 510,084 | 1.99 | 289.18 | 510,084 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 392,896 | 1.48 | 222.75 | 392,896 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life Frontline Equity Fund | 329,435 | 0.71 | 186.77 | 329,435 | 2025-04-22 17:25:14 | 0% |
| Nippon India Growth Fund | 303,512 | 0.7 | 172.07 | 303,512 | 2025-04-22 17:25:14 | 0% |
| HSBC Midcap Fund | 294,959 | 1.72 | 167.22 | 294,959 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life MNC Fund - Div | 280,976 | 4.49 | 159.3 | 280,976 | 2025-04-22 17:25:14 | 0% |
| Aditya Birla Sun Life MNC Fund - Gr | 280,976 | 4.49 | 159.3 | 280,976 | 2025-04-22 17:25:14 | 0% |
| Kotak Flexicap Fund - Regular Plan | 215,000 | 0.27 | 121.89 | 215,000 | 2025-04-22 14:53:35 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 126.38 | 164.77 | 168.71 | 143.58 | 109.72 |
| Diluted EPS (Rs.) | 126.38 | 164.77 | 168.71 | 143.58 | 109.72 |
| Cash EPS (Rs.) | 145.41 | 181.40 | 186.57 | 158.08 | 126.19 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 634.83 | 634.61 | 604.03 | 562.20 | 568.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 634.83 | 634.61 | 604.03 | 562.20 | 568.00 |
| Dividend / Share (Rs.) | 125.00 | 140.00 | 130.00 | 150.00 | 115.00 |
| Revenue From Operations / Share (Rs.) | 1219.02 | 1136.57 | 1144.70 | 1054.43 | 949.06 |
| PBDIT / Share (Rs.) | 180.24 | 230.51 | 220.07 | 192.81 | 194.99 |
| PBIT / Share (Rs.) | 161.34 | 214.03 | 202.36 | 178.44 | 178.62 |
| PBT / Share (Rs.) | 157.55 | 209.66 | 220.51 | 188.60 | 176.95 |
| Net Profit / Share (Rs.) | 126.50 | 164.92 | 168.86 | 143.72 | 109.82 |
| PBDIT Margin (%) | 14.78 | 20.28 | 19.22 | 18.28 | 20.54 |
| PBIT Margin (%) | 13.23 | 18.83 | 17.67 | 16.92 | 18.82 |
| PBT Margin (%) | 12.92 | 18.44 | 19.26 | 17.88 | 18.64 |
| Net Profit Margin (%) | 10.37 | 14.51 | 14.75 | 13.63 | 11.57 |
| Return on Networth / Equity (%) | 19.92 | 25.98 | 27.95 | 25.56 | 19.33 |
| Return on Capital Employeed (%) | 23.96 | 32.03 | 31.31 | 29.74 | 30.05 |
| Return On Assets (%) | 10.82 | 16.10 | 16.20 | 14.82 | 11.63 |
| Asset Turnover Ratio (%) | 1.11 | 1.10 | 1.14 | 1.10 | 1.06 |
| Current Ratio (X) | 2.01 | 2.44 | 2.19 | 2.15 | 2.26 |
| Quick Ratio (X) | 0.94 | 1.48 | 1.18 | 1.24 | 1.41 |
| Inventory Turnover Ratio (X) | 1.84 | 1.48 | 1.39 | 1.82 | 2.17 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 81.93 | 74.09 | 104.47 | 104.82 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 74.48 | 67.06 | 94.98 | 91.22 |
| Earning Retention Ratio (%) | 0.00 | 18.07 | 25.91 | -4.47 | -4.82 |
| Cash Earning Retention Ratio (%) | 0.00 | 25.52 | 32.94 | 5.02 | 8.78 |
| Interest Coverage Ratio (X) | 47.61 | 52.81 | 44.31 | 67.11 | 69.48 |
| Interest Coverage Ratio (Post Tax) (X) | 34.41 | 38.78 | 30.35 | 46.49 | 39.73 |
| Enterprise Value (Cr.) | 21230.10 | 22377.29 | 17307.30 | 21584.03 | 22612.20 |
| EV / Net Operating Revenue (X) | 3.88 | 4.38 | 3.37 | 4.56 | 5.31 |
| EV / EBITDA (X) | 26.23 | 21.62 | 17.52 | 24.93 | 25.83 |
| MarketCap / Net Operating Revenue (X) | 4.04 | 4.61 | 3.54 | 4.73 | 5.59 |
| Retention Ratios (%) | 0.00 | 18.06 | 25.90 | -4.47 | -4.82 |
| Price / BV (X) | 7.76 | 8.26 | 6.70 | 8.86 | 9.34 |
| Price / Net Operating Revenue (X) | 4.04 | 4.61 | 3.54 | 4.73 | 5.59 |
| EarningsYield | 0.02 | 0.03 | 0.04 | 0.02 | 0.02 |
After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
- For Cash EPS (Rs.), as of Mar 25, the value is 145.41. This value is within the healthy range. It has decreased from 181.40 (Mar 24) to 145.41, marking a decrease of 35.99.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
- For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 140.00 (Mar 24) to 125.00, marking a decrease of 15.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,219.02. It has increased from 1,136.57 (Mar 24) to 1,219.02, marking an increase of 82.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 180.24. This value is within the healthy range. It has decreased from 230.51 (Mar 24) to 180.24, marking a decrease of 50.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 161.34. This value is within the healthy range. It has decreased from 214.03 (Mar 24) to 161.34, marking a decrease of 52.69.
- For PBT / Share (Rs.), as of Mar 25, the value is 157.55. This value is within the healthy range. It has decreased from 209.66 (Mar 24) to 157.55, marking a decrease of 52.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 126.50. This value is within the healthy range. It has decreased from 164.92 (Mar 24) to 126.50, marking a decrease of 38.42.
- For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has decreased from 20.28 (Mar 24) to 14.78, marking a decrease of 5.50.
- For PBIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 18.83 (Mar 24) to 13.23, marking a decrease of 5.60.
- For PBT Margin (%), as of Mar 25, the value is 12.92. This value is within the healthy range. It has decreased from 18.44 (Mar 24) to 12.92, marking a decrease of 5.52.
- For Net Profit Margin (%), as of Mar 25, the value is 10.37. This value exceeds the healthy maximum of 10. It has decreased from 14.51 (Mar 24) to 10.37, marking a decrease of 4.14.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has decreased from 25.98 (Mar 24) to 19.92, marking a decrease of 6.06.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.96. This value is within the healthy range. It has decreased from 32.03 (Mar 24) to 23.96, marking a decrease of 8.07.
- For Return On Assets (%), as of Mar 25, the value is 10.82. This value is within the healthy range. It has decreased from 16.10 (Mar 24) to 10.82, marking a decrease of 5.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has increased from 1.10 (Mar 24) to 1.11, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.44 (Mar 24) to 2.01, marking a decrease of 0.43.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.94, marking a decrease of 0.54.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.84. This value is below the healthy minimum of 4. It has increased from 1.48 (Mar 24) to 1.84, marking an increase of 0.36.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 81.93 (Mar 24) to 0.00, marking a decrease of 81.93.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 74.48 (Mar 24) to 0.00, marking a decrease of 74.48.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 18.07 (Mar 24) to 0.00, marking a decrease of 18.07.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 25.52 (Mar 24) to 0.00, marking a decrease of 25.52.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 47.61. This value is within the healthy range. It has decreased from 52.81 (Mar 24) to 47.61, marking a decrease of 5.20.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 34.41. This value is within the healthy range. It has decreased from 38.78 (Mar 24) to 34.41, marking a decrease of 4.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 21,230.10. It has decreased from 22,377.29 (Mar 24) to 21,230.10, marking a decrease of 1,147.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.38 (Mar 24) to 3.88, marking a decrease of 0.50.
- For EV / EBITDA (X), as of Mar 25, the value is 26.23. This value exceeds the healthy maximum of 15. It has increased from 21.62 (Mar 24) to 26.23, marking an increase of 4.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 18.06 (Mar 24) to 0.00, marking a decrease of 18.06.
- For Price / BV (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has decreased from 8.26 (Mar 24) to 7.76, marking a decrease of 0.50.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bayer CropScience Ltd:
- Net Profit Margin: 10.37%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.96% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.92% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 34.41
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.8 (Industry average Stock P/E: 35.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.37%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Bayer House, Central Avenue, Mumbai Maharashtra 400607 | ir_bcsl@bayer.com http://www.bayer.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pankaj Ramanbhai Patel | Chairman & Ind.Dire (Non-Exe) |
| Mr. Simon Thorsten Wiebusch | Vice Chairman & Mng.Director |
| Mr. Vinit Rajesh Jindal | Executive Director & CFO |
| Dr. Thomas Hoffmann | Non Exe.Non Ind.Director |
| Ms. Jana Marlen Ackermann | Non Exe.Non Ind.Director |
| Ms. Radhika Rajan | Ind. Non-Executive Director |
| Mr. Sekhar Natarajan | Ind. Non-Executive Director |
| Mr. Sanjiv Rangrass | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Bayer CropScience Ltd?
Bayer CropScience Ltd's intrinsic value (as of 12 October 2025) is 3930.29 which is 21.32% lower the current market price of 4,995.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹22,413 Cr. market cap, FY2025-2026 high/low of 6,912/4,217, reserves of ₹2,806 Cr, and liabilities of 5,246 Cr.
What is the Market Cap of Bayer CropScience Ltd?
The Market Cap of Bayer CropScience Ltd is 22,413 Cr..
What is the current Stock Price of Bayer CropScience Ltd as on 12 October 2025?
The current stock price of Bayer CropScience Ltd as on 12 October 2025 is 4,995.
What is the High / Low of Bayer CropScience Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bayer CropScience Ltd stocks is 6,912/4,217.
What is the Stock P/E of Bayer CropScience Ltd?
The Stock P/E of Bayer CropScience Ltd is 37.8.
What is the Book Value of Bayer CropScience Ltd?
The Book Value of Bayer CropScience Ltd is 634.
What is the Dividend Yield of Bayer CropScience Ltd?
The Dividend Yield of Bayer CropScience Ltd is 2.50 %.
What is the ROCE of Bayer CropScience Ltd?
The ROCE of Bayer CropScience Ltd is 24.8 %.
What is the ROE of Bayer CropScience Ltd?
The ROE of Bayer CropScience Ltd is 20.0 %.
What is the Face Value of Bayer CropScience Ltd?
The Face Value of Bayer CropScience Ltd is 10.0.